To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

NCT ID: NCT04747977

Last Updated: 2023-02-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

172 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-12

Study Completion Date

2021-09-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Randomized, double-masked, vehicle-controlled, phase 2 study evaluating the efficacy and safety of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of signs and symptoms of Dry Eye Disease (DED). The subjects will be followed for approximately 2-3 months from screening to the last visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OTX-DED 0.2mg

Approximately 50 subjects

Group Type EXPERIMENTAL

OTX-DED

Intervention Type DRUG

0.2mg dexamethasone ophthalmic insert

OTX-DED 0.3mg

Approximately 50 subjects

Group Type EXPERIMENTAL

OTX-DED

Intervention Type DRUG

0.3mg dexamethasone ophthalmic insert

Hydrogel Vehicle (HV)

Approximately 50 subjects

Group Type PLACEBO_COMPARATOR

OTX-DED

Intervention Type DRUG

Hydrogel vehicle ophthalmic insert

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OTX-DED

0.2mg dexamethasone ophthalmic insert

Intervention Type DRUG

OTX-DED

0.3mg dexamethasone ophthalmic insert

Intervention Type DRUG

OTX-DED

Hydrogel vehicle ophthalmic insert

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Dry Eye Disease diagnosis
* VAS eye dryness severity score ≥ 40.

Exclusion Criteria

* Are unwilling to discontinue use of contact lenses
* Are unwilling to withhold use of artificial tears.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ocular Therapeutix, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ocular Therapeutix

Inglewood, California, United States

Site Status

Ocular Therapeutix, Inc

Mission Hills, California, United States

Site Status

Ocular Therapeutix, Inc.

Newport Beach, California, United States

Site Status

Ocular Therapeutix, Inc.

Santa Ana, California, United States

Site Status

Ocular Therapeutix, Inc.

Delray Beach, Florida, United States

Site Status

Ocular Therapeutix, Inc.

Largo, Florida, United States

Site Status

Ocular Therapeutix

Warrenville, Illinois, United States

Site Status

Ocular Therapeutix, Inc.

Indianapolis, Indiana, United States

Site Status

Ocular Therapeutix

Kansas City, Missouri, United States

Site Status

Ocular Therapeutix, Inc.

St Louis, Missouri, United States

Site Status

Ocular Therapeutix

Poughkeepsie, New York, United States

Site Status

Ocular Therapeutix, Inc.

Raleigh, North Carolina, United States

Site Status

Ocular Therapeutix, Inc.

Cranberry Township, Pennsylvania, United States

Site Status

Ocular Therapeutix, Inc.

Memphis, Tennessee, United States

Site Status

Ocular Therapeutix, Inc.

League City, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OTX-DED-2020-201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dextenza With ILUX for Treatment of MGD
NCT04658927 COMPLETED PHASE4